Sofinnova

Sofinnova is the name shared by two formerly-related venture capital firms, Sofinnova Ventures and Sofinnova Partners. Both firms trace their roots back to Sofinnova SA, an investment institution founded in Paris in 1972. The two firms have raised nearly $3B combined since inception, and share the similar investment strategies of investing in the life science and technology sectors. The two sister firms distinguish themselves on the basis of their target geographies, and have been fully independent since 1997.

• Sofinnova Ventures has offices in Menlo Park, CA and San Diego, CA and focuses largely on US biotech investments, with ~20% allocation for Europe.
• Sofinnova Partners is based in Paris and focuses primarily on European biotech and cleantech investments, with a similar reciprocal allocation for the US.

Sofinnova Ventures and Sofinnova Partners have had historically some of the same Limited Partners, and have co-invested together in selected companies from their respective funds. Both firms work together in a collegial way to exchange information and due diligence in each other's respective geographies. The firms do not have an obligation to show each other deals or to co-invest, but historically have co-invested together in ~10% of their collective investments.

Sofinnova Ventures (USA)

Sofinnova Ventures

Type	Private
Industry	Private Equity
Founded	1974
Headquarters	Menlo Park, CA, USA
Key people	Jim Healy, MD, PhD, Mike Powell, PhD, Garheng Kong, MD, PhD, Anand Mehra, MD, Eric Buatois, Brian Wilcove, Lars Ekman, MD, David Kabakoff, PhD, Nathalie Auber, Alain Azan (Retired), Jean Deleage (Deceased)
Products	Venture Capital
Total assets	$1.4B[1]
Employees	~20
Website	www.sofinnova.com

Sofinnova Ventures is an independent venture capital firm based in Menlo Park with $1.4B capital under management.^[1]

Investments

Sofinnova Ventures has been an active venture investor, investing in some well known venture investments of the period. Sofinnova invested in Collagen Aesthetics, Biogen, Genentech, Tandon, Tandem Computers and Printonix, Tumbleweed, and Phone.com. Sofinnova Ventures funded several of these as start-ups that developed into large international companies. More recently, Sofinnova Ventures has backed companies including: Kosan Biosciences, Actelion, Intermune, Seattle Genetics, Cotherix, Threshold Pharmaceuticals, Prestwick, Preglem, Movetis, Intellikine and Amarin.

The San Francisco office of Sofinnova Ventures was often remembered for having an original 18 ft. mosasaurus in the office of one of the Managing Partners (Mike Powell). Sofinnova Ventures closed their San Francisco office in 2011, and combined their Bay Area offices into a single office on Sand Hill Road in Menlo Park.

The following funds have been raised by Sofinnova Ventures. The earlier funds of the SVP series were predominantly information technology (IT), wherein the later funds were predominantly life science focused. SVP VIII has a life science focus only, with emphasis on Phase 2 and 3 drug development. SVP IV was Sofinnova's initial fund after the reorganization of Sofinnova (see below).

• 1984 - $6M - Sofinnova Venture Partners I
• 1991 - $20M - Sofinnova Venture Partners II
• 1994 - $31M - Sofinnova Venture Partners III
• 1998 - $72M - Sofinnova Venture Partners IV
• 2000 - $210M - Sofinnova Venture Partners V
• 2003 - $250M - Sofinnova Venture Partners VI^[2][3]
• 2007 - $375M - Sofinnova Venture Partners VII^[4][5]
• 2011 - $440M - Sofinnova Venture Partners VIII

Source: Private Equity Intelligence and Sofinnova Ventures.

Sofinnova Partners (France)

Sofinnova Partners

Type	Private
Industry	Private Equity
Founded	1972
Headquarters	Paris, France
Key people	Denis Lucquin, Antoine Papiernik, Rafaele Tordjman, Graziano Seghezzi, Monique Saulnier, Jean-Bernard Schmidt (retired), Jean Deleage (deceased)
Products	Venture Capital
Total assets	€1.2 billion[1]
Website	www.sofinnova.fr

Sofinnova Partners is an independent venture capital firm based in Paris with approximately €1.2 billion of capital.^[1] The firm invests in early stage companies and corporate spin-offs, in information technology/cleantech and life science:

Sofinnova has financed more than 460 companies in Europe since inception 1972 of which more than 20% have successfully completed an initial public offering and more than 20% have been acquired by strategic buyers.

Investments

Following the separation of the two firms, Sofinnova Partners completed fundraising for its third private equity fund, Sofinnova Capital III with €121 million of capital. Among the investments in this fund are Innate, Maximiles and NovusPharma. Sofinnova's fourth fund which raised €330 million of capital made Sofinnova one of the largest venture firms in Europe at the time.

Sofinnova closed its fifth fund with €385M in 2005. That same year, in 2005, Sofinnova was named “Fund of the Year” by Private Equity International and “VC Techno House of the Year 2005” by the European Venture Capital Journal (EVCJ) which described Sofinnova's fundraising as the “Fundraising of the Year 2005”. This fund has invested in a number of companies including Taptu.

• 1989 - €38M - Sofinnova Capital I
• 1994 - €47M - Sofinnova Capital II
• 1998 - €121M - Sofinnova Capital III(first independent fund)
• 2001 - €330M - Sofinnova Capital IV
• 2005 - €385M - Sofinnova Capital V^[6]
• 2010 - €260M - Sofinnova Capital VI^[7]

Source: Private Equity Intelligence

History

History of private equity and venture capital

Early history (Origins of modern private equity) • The 1980s (Leveraged buyout boom) • The 1990s (Leveraged buyout and the venture capital bubble) • The 2000s (Dot-com bubble to the credit crunch)

v t e

The Founding of Sofinnova in the 1970s

• 1972 - Sofinnova was founded with the backing of several French financial institutions (most notably Crédit National) and was notable at the time for creating the first "American style" venture capital firm in France. Peter Brooke, the founder of TA Associates, was a board member of Sofinnova SA in its early years. Sofinnova SA quickly established a presence in the European market through the formation of Sofinnova Partners in Paris. Sofinnova SA owned this firm from 1972 until 1997.

• 1974 - Sofinnova became the first European venture company to enter the US market launching its US affiliate, Sofinnova, Inc (Sofinnova Ventures). Sofinnova co-founder, Jean Deleage, who would later co-found US venture firm Burr, Egan, Deleage & Co., was appointed the head of the US operation. Sofinnova's US business gained attention for its role as an early backer of Tandem Computers and Genentech in the early 1980s.

• 1976 - Sofinnova co-founder Jean Deleage established the American subsidiary of Sofinnova, called Sofinnova, Inc., in San Francisco, which eventually became Sofinnova Ventures. Deleage departed Sofinnova in 1979 to co-found another venture capital firm Burr, Egan, Deleage & Co.. In 1981, working with Deleage, Sofinnova developed a partnership with Burr, Egan, Deleage & Co. and ultimately other US firms. Jean-Bernard Schmidt, who would later serve as Chairman of Sofinnova, was named the head of US operations of Sofinnova, Inc.

The Early Growth of Sofinnova in the 1980s

• 1985 - Sofinnova completed an initial public offering with a listing on the Paris Stock Exchange.

• 1987 - Alain Azan moved to San Francisco to take over management of Sofinnova Ventures, replacing Jean-Bernard Schmidt. Schmidt would be named Chairman of Sofinnova, retaining that position through 2007. Sofinnova Ventures completed fundraising for SVP I, which was an private equity fund originally intended to invest in European companies expanding in the US. Ultimately, Sofinnova Venture Partners would shift its focus toward investments in domestic US companies.

• 1989 - Sofinnova Partners completed fundraising for Sofinnova Capital, its first private equity fund in France, with €38M of investor commitments. Sofinnova's investments in this fund include Genset Corporation as well as Cerep, Egide and Flamel.

The Reorganization of Sofinnova in the 1990s

• 1993 - Sofinnova delisted itself from the Paris exchange to raise capital privately through traditional private equity funds. Prior to the 1997 reorganization, Sofinnova Ventures raised three venture funds totaling $57M, and Sofinnova Partners raised funds with €85M in commitments.

• 1997 - The global Sofinnova organization restructured, formally creating two separate management companies, one for Sofinnova Ventures, and one for Sofinnova Partners. The reorganization was done on the basis of geography, creating Sofinnova Ventures in the US and Sofinnova Partners in Europe. Following a management buyout, each of the management companies was solely owned by its respective management teams.

References

Sofinnova Ventures

Sofinnova Partners

External links

• Sofinnova Ventures (US) - company website
• Sofinnova Partners (France) - company website

v t e Private equity and venture capital investment firms Investment strategy Venture Growth Mezzanine Secondaries Leveraged buyout History History of private equity and venture capital Early history of private equity Private equity in the 1980s Private equity in the 1990s Private equity in the 2000s Investors Angel investor Corporate venture capital Commercial bank Crowdfunding Institutional investor Insurance company Investment bank Endowment Family office Fund of funds High-net-worth individual Merchant bank Pension fund Sovereign wealth fund Private equity firms Venture capital firms Portfolio companies